Drugs / Pemetrixed
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT04425135 Background | Jul 2020 → Jan 2023 | lung neoplasm | The First Affiliated Hospital of Xiamen University | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Pemetrixed | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04425135 ↗ |
| Route | Intravenous | “500 mg/m2,D1,ivgtt, Q3w.” NCT04425135 ↗ |